About Splice Bio
Splice Bio is a company based in Barcelona (Spain) founded in 2020. Splice Bio has raised $191.7 million across 3 funding rounds from investors including Roche, EQT and Ysios Capital. Splice Bio offers products and services including Protein Splicing Platform and SB-007. Splice Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Barcelona, Spain
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Splicebio, S.L.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$191.7 M (USD)
in 3 rounds
-
Latest Funding Round
$135 M (USD), Series B
Jun 11, 2025
-
Investors
Roche
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Splice Bio
Splice Bio offers a comprehensive portfolio of products and services, including Protein Splicing Platform and SB-007.
Technology for developing advanced gene therapies for genetic diseases.
Dual-AAV treatment targeting Stargardt disease through clinical trials.
People of Splice Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Splice Bio
Splice Bio has successfully raised a total of $191.7M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Splice Bio
Splice Bio has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, EQT and Ysios Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ysios Capital is recognized as a leading life sciences investor.
|
Locked | Locked | Locked | |
|
UCB Ventures is focused on strategic corporate venture investments.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Splice Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Splice Bio
Investment portfolio details for Splice Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Splice Bio
Detailed financials for Splice Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Splice Bio Comparisons
Peer comparison for Splice Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Splice Bio
Splice Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Splice Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Splice Bio
Complete news archive for Splice Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Splice Bio
Splice Bio was founded in 2020.
Splice Bio is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Splice Bio is a funded company, having raised a total of $191.7M across 3 funding rounds to date.
Splice Bio was founded in 2020 in Barcelona, Spain, within the biotechnology sector. A proprietary intein platform technology is provided to address rare genetic diseases through gene therapy. Operations center on developing treatments, with the lead program targeting Stargardt disease, an inherited retinal disorder linked to ABCA4 gene mutations. The platform enables precise genetic interventions for affected patients.
Splice Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Splice Bio offers Protein Splicing Platform and SB-007.
Splice Bio has 10 investors. Key investors include Roche, EQT, Ysios Capital, UCB Ventures, and NEA.